Stocklytics Platform
Asset logo for symbol EOLS
Evolus
EOLS55
$15.17arrow_drop_up0.53%$0.08
Asset logo for symbol EOLS
EOLS55

$15.17

arrow_drop_up0.53%
Key Stats
Open$14.55
Prev. Close$14.71
EPS-0.90
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range14.52
15.59
52 Week Range7.44
16.29
Ratios
EPS-0.90
Fundamentals
Payout Ratio-
Industry average yield2.94%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

EOLS-
US Healthcare Sector-
US Market-
warning

EOLS / Market

EOLS lose to the US Market which returned -1.02% over the last twenty four hours.
warning

EOLS / Healthcare Sector

EOLS lose to the US Healthcare sector which returned -0.54% over the last twenty four hours.

Evolus (EOLS) Statistics

Evolus Inc (EOLS) is a biotechnology company that specializes in developing and commercializing innovative aesthetic medical products. As of the latest statistics, EOLS stock has been performing well, outperforming the sector average. The stock's valuation metrics also indicate a positive outlook for the company. With a favorable enterprise-to-EBITDA ratio and a strong profit margin, Evolus Inc demonstrates its ability to generate significant returns for its shareholders. Furthermore, the company has managed to maintain a healthy balance sheet with a manageable level of total debt. This allows Evolus Inc to invest in research and development efforts and expand its product portfolio.
One of the key factors contributing to Evolus Inc's success is its strong revenue per share growth. The company's dedication to developing innovative aesthetic medical products has resulted in a steady increase in its revenue per share. This growth is expected to continue in the coming years as Evolus Inc introduces new products to the market. Additionally, the company's gross profit margin is impressive, indicating its ability to generate substantial profits from its operations. This is a testament to the effectiveness and market demand for Evolus Inc's products.
add Evolus  to watchlist

Keep an eye on Evolus

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the EBITDA of Evolus (EOLS) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Evolus (EOLS) is -$24.64M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How has Evolus (EOLS) stock's performance compared to its sector and the market over the past year?

Over the past year, Evolus (EOLS) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.03%, Evolus has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 60.21%, it has fallen short of the market average. This comparison highlights Evolus 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Evolus (EOLS) stock?

The PE ratio for Evolus (EOLS) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Evolus (EOLS) stock?

The Earnings Per Share (EPS) for Evolus (EOLS), calculated on a diluted basis, is -$0.9. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Evolus (EOLS) stock?

The operating margin for Evolus (EOLS) is -9.11%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

How much debt does Evolus (EOLS) have?

Evolus (EOLS) has a total debt of $126.75M. The net debt, which accounts for cash and cash equivalents against the total debt, is $33.08M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media